Mundipharma
Tina Hawkins Chartered MCIPD has extensive experience in human resources spanning from 1995 to the present, with a strong focus on talent development and organizational culture in the pharmaceutical industry. Currently serving as Vice President of Talent, Culture and Development at Mundipharma since July 2015, Tina has held various leadership roles within the company, including Vice President of Organizational Development and Head of Human Resources. Prior HR roles include positions at BARD Pharmaceuticals Limited, Mundipharma International, Syngenta, VoiceAbility, and Marriott. Tina's educational background includes an Advanced Diploma in Human Resources Management from CIPD and qualifications from The Open University and other institutions.
This person is not in any teams
This person is not in any offices
Mundipharma
5 followers
The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries. In Europe, the network employees more than 2,000 employees from R&D to manufacturing & supply and commercial, and with revenues in excess of €1 billion. At Mundipharma we strive for one high performing and learning environment where individuals can make a real difference. We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. We have built a European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as diabetes, respiratory, oncology, pain and biosimilars.